1469337-91-4

Basic information

• Product Name: K-Ras(G12C) inhibitor 9
• Synonyms: K-Ras(G12C) inhibitor 9;N-[1-[2-[(4-chloro-5-iodo-2-methoxyphenyl)amino]acetyl]-4-piperidinyl]-ethenesulfonamide
• CAS NO: 1469337-91-4
• Molecular Formula: C16H21ClIN3O4S
• Molecular Weight: 513.77811
• EINECS: -0
• Product Categories: Inhibitors
• Mol File: 1469337-91-4.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 656.3±65.0 °C(Predicted)
• Appearance: /
• Density: 1.68±0.1 g/cm3(Predicted)
• Solubility: Soluble in DMSO
• PKA: 9.68±0.20(Predicted)
• CAS DataBase Reference: K-Ras(G12C) inhibitor 9(CAS DataBase Reference)
• NIST Chemistry Reference: K-Ras(G12C) inhibitor 9(1469337-91-4)
• EPA Substance Registry System: K-Ras(G12C) inhibitor 9(1469337-91-4)

Safety Data

• Hazardous Substances Data: 1469337-91-4(Hazardous Substances Data)

Usage

Description

K-Ras(G12C) inhibitor 9 is an irreversible, allosteric inhibitor specifically designed to target the K-Ras(G12C) mutant protein, which is associated with the promotion of cancer. This inhibitor modifies the protein 100% when used at a concentration of 10 μM for 24 hours in vitro. The K-Ras protein is a small GTPase that alternates between a GTP-bound active state and a GDP-bound inactive state, regulating cell growth by activating downstream Raf kinases. The G12C mutation in K-Ras impairs GTP hydrolysis, leading to the activation of K-Ras and the promotion of carcinogenesis. K-Ras(G12C) inhibitor 9 effectively reduces GTP affinity relative to GDP, decreases Raf binding, and lowers cell viability while increasing apoptosis.

Uses

Used in Oncology:
K-Ras(G12C) inhibitor 9 is used as an allosteric inhibitor for the treatment of cancers driven by the K-Ras(G12C) mutation. It works by modifying the K-Ras(G12C) protein, reducing its GTP affinity, decreasing Raf binding, and ultimately lowering cell viability while promoting apoptosis. This targeted approach offers a potential therapeutic strategy for patients with K-Ras(G12C)-mutated cancers, which are often resistant to conventional treatments.
Used in Drug Development:
K-Ras(G12C) inhibitor 9 serves as a valuable compound in the development of novel cancer therapies. Its unique mechanism of action and specificity for the K-Ras(G12C) mutant make it an important tool for researchers to study the role of K-Ras in cancer and to develop more effective treatments for patients with K-Ras(G12C)-mutated tumors.
Used in Preclinical Research:
K-Ras(G12C) inhibitor 9 is used as a research tool in preclinical studies to investigate the effects of inhibiting the K-Ras(G12C) protein on cancer cell growth, survival, and apoptosis. This helps researchers understand the underlying molecular mechanisms of K-Ras(G12C) in carcinogenesis and evaluate the potential of this inhibitor as a therapeutic agent in various cancer models.
Used in Drug Combination Strategies:
K-Ras(G12C) inhibitor 9 can be used in combination with other cancer therapies to enhance treatment efficacy. By targeting the K-Ras(G12C) protein, this inhibitor may sensitize cancer cells to other treatments, such as chemotherapy or immunotherapy, potentially leading to improved outcomes for patients with K-Ras(G12C)-mutated cancers.
Used in Personalized Medicine:
K-Ras(G12C) inhibitor 9 is used as a component of personalized medicine approaches, where treatments are tailored to the specific genetic mutations present in a patient's tumor. By targeting the K-Ras(G12C) mutation, this inhibitor can provide a more targeted and effective treatment option for patients with this specific genetic profile.
Used in Pharmaceutical Industry:
K-Ras(G12C) inhibitor 9 is used as a lead compound in the pharmaceutical industry for the development of new drugs targeting the K-Ras(G12C) mutation. Its unique properties and specificity make it an attractive starting point for the design and optimization of novel therapeutic agents for the treatment of K-Ras(G12C)-mutated cancers.

in vitro

k-ras(g12c) inhibitor 9 belongs to a series of small molecules, which irreversibly compete with gtp and gdp for binding to a common oncogenic k-ras(g12c) mutant and blocked the association of b-raf and c-raf with k-ras(g12c). k-ras(g12c) inhibitor 9 (10 μm) decreased viability and increased apoptosis of g12c mutations-containing lung cancer cell lines (h1792, calu-1, h358, and h23) [1].

target

k-ras(g12c)

references

1. ostrem jm, peters u, sos ml, wells ja, shokat km. k-ras(g12c) inhibitors allosterically control gtp affinity and effector interactions. nature. 2013;503(7477):548-51. 2. hunter jc, gurbani d, ficarro sb, carrasco ma, lim sm, choi hg, et al. in situ selectivity profiling and crystal structure of sml-8-73-1, an active site inhibitor of oncogenic k-ras g12c. proc natl acad sci u s a. 2014;111(24):8895-900. 3. lim sm, westover kd, ficarro sb, harrison ra, choi hg, pacold me, et al. therapeutic targeting of oncogenic k-ras by a covalent catalytic site inhibitor. angew chem int ed engl. 2014;53(1):199-204.